II. Pathophysiology
- Acute Hepatitis B Infection becomes chronic in 10%
-
Chronic Hepatitis B (HBsAg present >6 months)
- Chronic Hepatitis B Carrier
- Chronic Hepatitis B Infection
- Hepatitis B Carrier contrasted with chronic HBV infection
- Low viral load
- Normal Liver Function Tests (ALT or SGPT)
III. Risk Factors
- Infants exposed in the first years of life (80-90% risk)
- Children age <6 years (30 to 50% risk)
IV. Symptoms
- Asymptomatic
V. Labs
- HBsAg positive
- HBeAg negative
- xHBeAb positive
- Low viral load: HBV DNA hybridization negative
-
Liver Function Tests (ALT or SGPT) normal
- Contrast with HBeAg-/xHBeAb+ Chronic Hepatitis B Infection (see precautions below)
VI. Precautions: HBeAg-/xHBeAb+ Chronic Hepatitis B Infection
- A subset of Hepatitis B "Carriers" have chronic active Hepatitis Despite HBeAg-/xHBeAb+
- Wildtype HBV may fail to produce HBeAg despite chronic HBV active or persistent infection
-
HBeAg-/xHBeAb+ Chronic Hepatitis B Infections are associated with elevated liver enzymes
- Contrast with HBV inactive carriers who have persistently normal liver enzymes
-
HBeAg-/xHBeAb+ Chronic Hepatitis B are at high risk for Chronic Hepatitis B complications
- Complications include Cirrhosis and Hepatocellular Carcinoma
- Contrast with a relatively benign course for inactive carriers with persistently normal liver enzymes
- HBV Carrier state liver enzyme monitoring is therefore critical to differentiate inactive carriers from chronic HBV
- In the first year of diagnosis, obtain liver enzyme monitoring every 3 months
- Thereafter, obtain liver enzymes periodically (every 6-12 months)
- HBeAg-/xHBeAb+ Chronic Hepatitis B is treated as Chronic Hepatitis B Infection
- References
VII. Management
- Recheck liver transaminases every 3 months for the first year of diagnosis
- Differentiate inactive carrier from HBeAg-/xHBeAb+ Chronic Hepatitis B Infection (see precautions above)
- Observation: primary care visits every 6-12 months
- Follow related lab-work at follow-up visits
- Liver Function Tests (ALT or SGPT)
- HBsAg
- HBeAg
- xHBeAb
VIII. Course
- Spontaneous clearance in 1% of carriers per year
- Risk of reactivation to Chronic Hepatitis B Infection
- Immunosuppression (e.g. Chemotherapy, Immunotherapy, organ transplant)
- HCV coinfection
IX. Prevention: Transmission to Others
- Identify all potential exposures
- Children
- Household contacts
- Sexual contacts
- Hepatitis B Serology testing for all exposures
- Hepatitis B Vaccine for all exposures not immune
X. References
- Berenguer in Feldman (2002) Sleisenger GI, p. 1285-303
- Lok (2001) Hepatology 34:1225-41 [PubMed]
- Malik (2000) Ann Intern Med 132:723-31 [PubMed]